Brachytherapy Results for Low- and Intermediate-risk Prostate Cancer Treated at Mayo Clinic

According to a retrospective study published this month in the journal Brachytherapy,  permanent low-dose-rate (LDR)  prostate brachytherapy monotherapy with I-125 has worked well for men with low-and intermediate-risk prostate cancer.

Investigating outcomes for a series of 974 patients treated at the Mayo with this type of permanent “seed” implant brachytherapy¬† analysts focused on factors associated with biochemical failure and survival. Continue reading “Brachytherapy Results for Low- and Intermediate-risk Prostate Cancer Treated at Mayo Clinic”

Shorter Androgen Blockade for High-Risk Prostate Cancer Patients Treated with Radiotherapy: Trial Results

Reducing ADT from 36 to 18 months Improves Quality of Life, Does Not Reduce Survival

A randomized Phase III Trial of outcomes for high-risk prostate cancer patients treated with radiotherapy and either 36 or 18 months of androgen deprivation therapy has found “no difference in survival between the two groups, with the 18-month group experiencing a better quality of life.”

Survival and biochemical failure rates between 36 months and 18 months of ADT combined with Radiotherapy for men with high-risk prostate. cancer ).

Continue reading “Shorter Androgen Blockade for High-Risk Prostate Cancer Patients Treated with Radiotherapy: Trial Results”

Brachytherapy combination improves PSA-free Survival for patients with higher-risk localized prostate cancer, trial finds

Brachytherapuy seeds placement
Brachytherapy – where seeds are placed.

April 29, 2015. Many patients with higher-risk localized prostate cancer are treated with external beam radiation or with brachytherapy (seed implants). A clinical trial conducted by Dr James Miller (right) of Vancouver, Canada has found that patients receiving permanent implant brachytherapy “seeds” plus a boost of radiation have a better chance of long-term survival than those treated with higher dose-escalated external beam radiotherapy but without the implants.

Men receiving the radioactive “seeds” were more likely to be cancer-free five to nine years later. Continue reading “Brachytherapy combination improves PSA-free Survival for patients with higher-risk localized prostate cancer, trial finds”